BioSpace News Archive

Genetown

Wave Life Sciences to Develop Programs in Rare, Genetic Eye Diseases

Research will focus on inherited retinal diseases associated with RHO, USH2A, ABCA4 and CEP290

October 11, 2018
·
5 min read
Business

Ziopharm and Precigen Redefine Relationships, Announce New License Agreement

Ziopharm to Host Conference Call at 8 a.m.

October 11, 2018
·
9 min read
Genetown

TESARO Announces Data Presentations at the ESMO 2018 Congress

TESARO, Inc. today announced that data from six abstracts will be presented at the European Society for Medical Oncology (ESMO) Congress from October 19-23, 2018 in Munich, Germany.

October 11, 2018
·
5 min read
ABCAM PLC: New PBS-Only Antibodies Enable More Flexible Research

Abcam’s new phosphate buffered saline (PBS)-only recombinant antibodies are free from preservatives and stabilising agents, offering improved flexibility for researchers conducting more complex experiments.

October 11, 2018
·
2 min read
Business

Vitaccess and Pharnext Launch International CMT&Me Observational Study

Vitaccess and Pharnext SA today announced the launch of an international study on Charcot Marie Tooth disease (CMT) using a bespoke digital app named CMT&Me.

October 11, 2018
·
5 min read
Drug Development

FDA Lifts Clinical Hold; Green-Lights Vertex and CRISPR’s Sickle Cell Gene Therapy Trial

In May the FDA placed a hold on the trial and IND for CTX001, an investigational gene editing treatment, citing concerns over questions that had not been addressed in the IND.

October 11, 2018
·
3 min read
·
Alex Keown
Deals

Focused on Off-The-Shelf CAR-T, Allogene Therapeutics Hits the Nasdaq at $18 per Share

Allogene Therapeutics began trading on the Nasdaq Stock Exchange today under the ALLO ticker. The price was at the top of its range, $18 per share. The company plans to raise $288 million with the sale of about 16 million shares.

October 11, 2018
·
3 min read
·
Mark Terry
Policy

Trump Signs FTC Law That Allows for Biosimilar Scrutiny

President Donald Trump signed a bill into law yesterday that requires pharmaceutical companies to provide details of biosimilar deals to the Federal Trade Commission (FTC) for antitrust scrutiny.

October 11, 2018
·
3 min read
·
Mark Terry
Business

Ionis and Roche Ink Deal Worth More Than $700 Million for Dry AMD Treatment Collaboration

Ionis Pharmaceuticals is on a roll. Days after securing regulatory approval from the FDA for Tegsedi, the company inked a deal worth more than $700 million with pharma giant Roche to develop IONIS-FB-L for the treatment of complement-mediated diseases.

October 11, 2018
·
2 min read
·
Alex Keown
Drug Development

NIH’s Undiagnosed Diseases Network Identifies 31 New Syndromes

Examples of new syndromes include hypotonia, ataxia, and delayed development syndrome (HADDS) and Sashi-Pena syndrome (SHAPNS).

October 11, 2018
·
3 min read
·
Mark Terry